12/3
08:00 am
crnx
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
High
Report
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
11/20
04:05 pm
crnx
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
Low
Report
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
11/10
04:28 pm
crnx
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/9
06:40 pm
crnx
Crinetics Pharmaceuticals (CRNX): Valuation in Focus After FDA Approval and Positive PALSONIFY Launch Momentum [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals (CRNX): Valuation in Focus After FDA Approval and Positive PALSONIFY Launch Momentum [Yahoo! Finance]
11/8
11:45 pm
crnx
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday [Yahoo! Finance]
Low
Report
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday [Yahoo! Finance]
11/7
08:48 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target lowered by analysts at Citizens Jmp from $143.00 to $108.00. They now have a "market outperform" rating on the stock.
Low
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target lowered by analysts at Citizens Jmp from $143.00 to $108.00. They now have a "market outperform" rating on the stock.
11/6
04:21 pm
crnx
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/6
04:05 pm
crnx
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
10/23
08:00 am
crnx
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Low
Report
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
10/10
04:54 pm
crnx
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/10
04:41 pm
crnx
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/9
12:55 am
crnx
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) [Yahoo! Finance]
Low
Report
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) [Yahoo! Finance]
10/6
04:20 pm
crnx
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 [Yahoo! Finance]
10/6
04:05 pm
crnx
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Low
Report
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
10/1
05:11 am
crnx
Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug [Yahoo! Finance]
Low
Report
Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug [Yahoo! Finance]
9/30
12:02 pm
crnx
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval [Yahoo! Finance]
Low
Report
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval [Yahoo! Finance]
9/30
09:47 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $73.00 to $87.00. They now have an "outperform" rating on the stock.
Low
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $73.00 to $87.00. They now have an "outperform" rating on the stock.
9/30
04:10 am
crnx
JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating [Yahoo! Finance]
Medium
Report
JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating [Yahoo! Finance]
9/29
01:17 pm
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Morgan Stanley from $65.00 to $77.00. They now have an "overweight" rating on the stock.
Low
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Morgan Stanley from $65.00 to $77.00. They now have an "overweight" rating on the stock.
9/29
08:47 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Leerink Partners from $80.00 to $88.00. They now have an "outperform" rating on the stock.
Medium
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Leerink Partners from $80.00 to $88.00. They now have an "outperform" rating on the stock.
9/28
09:04 am
crnx
Is Crinetics Pharmaceuticals Stock a Buy? [Yahoo! Finance]
Medium
Report
Is Crinetics Pharmaceuticals Stock a Buy? [Yahoo! Finance]
9/26
01:17 pm
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "neutral" rating on the stock.
Low
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "neutral" rating on the stock.
9/26
08:17 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at JMP Securities from $86.00 to $143.00. They now have a "market outperform" rating on the stock.
High
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at JMP Securities from $86.00 to $143.00. They now have a "market outperform" rating on the stock.
9/26
08:16 am
crnx
Orsini Selected as Specialty Pharmacy Partner for Crinetics' PALSONIFY™ (paltusotine) [Yahoo! Finance]
High
Report
Orsini Selected as Specialty Pharmacy Partner for Crinetics' PALSONIFY™ (paltusotine) [Yahoo! Finance]
9/26
08:05 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Robert W. Baird from $58.00 to $62.00. They now have an "outperform" rating on the stock.
High
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Robert W. Baird from $58.00 to $62.00. They now have an "outperform" rating on the stock.